Pedro Valdivielso Selected Research

Arteriosclerosis

11/2022	Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society.
9/2020	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®).
3/2020	Subclinical Arteriosclerosis is Associated With Common Vascular Risk Factors in Long-Term Survivors of Testicular Cancer.
5/2019	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019.
1/2019	Criteria for referring patients to Spanish Atherosclerosis Society lipid units.
11/2018	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society.
11/2017	National Dyslipidemia Registry of the Spanish Arteriosclerosis Society: Current status.
1/2017	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
3/2011	[Clinical features of patients with hypertriglyceridemia referred to lipid units: registry of hypertrigliceridemia of the Spanish Arteriosclerosis Society].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pedro Valdivielso Research Topics

Disease

11	Cardiovascular Diseases (Cardiovascular Disease) 03/2021 - 04/2010
10	Hypertriglyceridemia 01/2022 - 10/2002
9	Arteriosclerosis 11/2022 - 03/2011
6	Hypertension (High Blood Pressure) 07/2019 - 07/2008
5	Pancreatitis 01/2020 - 06/2009
5	Type 2 Diabetes Mellitus (MODY) 10/2014 - 10/2007
4	Hypercholesterolemia 11/2022 - 08/2002
4	Dyslipidemias (Dyslipidemia) 11/2022 - 01/2017
4	Atherosclerosis 01/2022 - 07/2012
3	Pseudoxanthoma Elasticum (Gronblad Strandberg Syndrome) 06/2021 - 12/2019
3	Obesity 09/2020 - 06/2009
3	Rheumatoid Arthritis 08/2020 - 01/2016
3	Inflammation (Inflammations) 03/2020 - 12/2015
3	Peripheral Arterial Disease 10/2014 - 07/2008
2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 11/2022 - 01/2019
2	Hyperlipidemias (Hyperlipidemia) 01/2022 - 01/2009
2	Inborn Genetic Diseases (Disease, Hereditary) 11/2021 - 05/2020
2	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 12/2020 - 11/2018
2	Costello Syndrome 12/2020 - 11/2018
2	Fatty Liver 03/2020 - 05/2017
2	Insulin Resistance 03/2020 - 01/2016
2	Homozygous Familial Hypercholesterolemia 01/2019 - 03/2015
1	Atherosclerotic Plaque (Atheroma) 01/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 11/2021
1	Body Weight (Weight, Body) 05/2021
1	Immunoglobulin G4-Related Disease 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2020
1	Testicular Neoplasms (Testicular Cancer) 03/2020
1	Prediabetic State (Prediabetes) 07/2019
1	Chronic Renal Insufficiency 01/2019
1	Vascular Calcification 01/2019
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2018
1	Arterial calcification of infancy 01/2018
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 09/2015
1	Diabetic Nephropathies (Diabetic Nephropathy) 09/2014
1	Vascular Diseases (Vascular Disease) 10/2007
1	Nephrotic Syndrome (Syndrome, Nephrotic) 04/2003

Drug/Important Bio-Agent (IBA)

18	LipidsIBA 11/2022 - 10/2007
11	Triglycerides (Triacylglycerol)IBA 01/2022 - 10/2007
5	LDL CholesterolIBA 11/2022 - 07/2008
5	ApolipoproteinsIBA 01/2022 - 02/2012
5	Lipoproteins (Lipoprotein)IBA 03/2021 - 01/2009
4	HDL CholesterolIBA 11/2022 - 07/2008
4	Apolipoprotein B-48IBA 01/2022 - 01/2009
3	CholesterolIBA 11/2021 - 05/2019
3	oxidized low density lipoproteinIBA 11/2021 - 03/2015
3	Apolipoproteins E (ApoE)IBA 02/2012 - 06/2009
2	CytokinesIBA 01/2022 - 01/2016
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 05/2021 - 01/2009
2	ChylomicronsIBA 12/2020 - 12/2015
2	EnzymesIBA 12/2019 - 01/2018
2	diphosphoric acid (pyrophosphoric acid)IBA 12/2019 - 01/2018
2	Blood Glucose (Blood Sugar)IBA 07/2019 - 04/2010
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 07/2019 - 07/2008
2	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 11/2018 - 06/2009
2	Apolipoprotein C-II (ApoC2)IBA 11/2018 - 06/2009
2	Lipase (Acid Lipase)FDA Link 06/2009 - 07/2008
2	Atorvastatin (Lipitor)FDA Link 04/2003 - 08/2002
1	C-Reactive ProteinIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Biomarkers (Surrogate Marker)IBA 06/2021
1	SugarsIBA 05/2021
1	Fibric Acids (Fibrates)IBA 05/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Apolipoproteins B (ApoB)IBA 12/2020
1	VLDL LipoproteinsIBA 12/2020
1	ElastinIBA 05/2020
1	CalciumIBA 03/2020
1	HDL LipoproteinsIBA 03/2020
1	Alkaline PhosphataseIBA 12/2019
1	PCSK9 InhibitorsIBA 05/2019
1	Apolipoprotein B-100 (Apo B 100)IBA 01/2019
1	Phosphorus (Red Phosphorus)IBA 01/2019
1	Proprotein Convertase 9IBA 01/2019
1	Apolipoprotein A-VIBA 11/2018
1	Chylomicron RemnantsIBA 02/2018
1	Adenosine Triphosphate (ATP)IBA 01/2018
1	ectonucleotide pyrophosphatase phosphodiesterase 1IBA 01/2018
1	A-factor (Streptomyces)IBA 01/2018
1	Olive OilIBA 05/2017
1	AdipokinesIBA 01/2016
1	Hemoglobins (Hemoglobin)IBA 09/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2012
1	Fluvastatin FDA Link 01/2009
1	Pharmaceutical PreparationsIBA 04/2003
1	Fenofibrate (CiL)FDA LinkGeneric 10/2002

Therapy/Procedure

5	Therapeutics 01/2019 - 08/2002
3	Secondary Prevention 11/2022 - 11/2018
2	Drug Therapy (Chemotherapy) 03/2020 - 06/2009
2	Mediterranean Diet 07/2017 - 05/2017
1	Bariatric Surgery 01/2022
1	Caloric Restriction 05/2021
1	Radiotherapy 03/2020
1	Tertiary Prevention 09/2015
1	Denervation 12/2012